查看購物車
  • Simplified Chinese
  • English
  • Japanese
基因融合檢測市場 - 全球及區域分析：按類別、技術、適應症、最終用戶及區域 - 分析與預測（2025-2035）
市場調查報告書
商品編碼
1714079

基因融合檢測市場 - 全球及區域分析：按類別、技術、適應症、最終用戶及區域 - 分析與預測（2025-2035）

Gene Fusion Testing Market - A Global and Regional Analysis: Focus on Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 130 Pages | 商品交期: 1-5個工作天內

價格

全球基因融合檢測市場是分子診斷和精準醫療的關鍵組成部分，專注於識別導致各種疾病（尤其是癌症）發展的基因變異，特別是基因融合。

這些測試檢測出可能導致蛋白質功能失調並推動癌症進展的基因重排。隨著對先進診斷技術的需求不斷增加，全球基因融合檢測市場正成為精準醫療不可或缺的一部分，從而能夠根據每位患者獨特的基因特徵制定個人化治療方案。該市場透過基於基因觀察實現更有針對性和更有效的治療，在改變癌症治療方面發揮關鍵作用。

在全球基因融合檢測市場中，次世代定序（NGS）、螢光原位雜合反應（FISH）和聚合酵素鏈鎖反應（PCR）等多種技術用於檢測各種癌症的基因融合。隨著技術的不斷進步，全球基因融合檢測市場預計將呈指數級成長，為早期診斷、精準治療選擇和改善患者預後提供新的機會。個人化醫療的需求不斷成長，進一步推動了全球基因融合檢測市場的發展，確保根據患者的基因組成量身定做治療，提高治療效果，並最大限度地減少副作用。

全球基因融合檢測市場正在經歷顯著成長，這得益於與基因融合突變相關的癌症盛行率的不斷上升。這種擴展是由對早期檢測、更好地選擇標靶治療和個人化醫療的日益成長的需求所推動的。此外，基因融合測試在臨床實踐中的應用日益廣泛，進一步加速了癌症治療中對這些診斷測試的需求。隨著全球基因融合檢測市場的不斷發展，基因融合檢測在為癌症患者提供更精準、個人化的治療方案、改善患者整體治療效果方面發揮關鍵作用。

基因融合測試是一種診斷程序，使用分子分析來檢測和測試被稱為基因融合的遺傳異常。當位於不同染色體區域的兩個不同基因異常結合形成混合基因時，就會發生基因融合。這種融合會導致異常蛋白質的產生或基因表現的改變，從而導致各種疾病的發展，包括某些癌症。癌症進展受到多種基因改變的影響，包括突變、缺失、擴增和重排，其中基因融合是重要因素。廈門診斷有限公司、Biocartis、Biocare Medical, LLC、丹納赫集團和 F. Hoffmann-La Roche Ltd. 等業界領先公司的參與預計將推動全球基因融合檢測市場的進一步成長。

此外，人工智慧預測模型可以識別可能需要額外診斷測試的患者，從而最大限度地減少耗時且昂貴的實驗室檢測需求。這些模型還可以發現先前未被發現的基因融合事件，提高對癌症基因組圖譜的了解，並有助於全球基因融合檢測市場開發標靶治療方法。

按類別分類，研究領域預計將在 2024 年引領全球基因融合檢測市場。套件、檢測試劑和配件的採用率不斷提高，為該領域的成長和主導地位做出了重大貢獻。這些僅用於研究的檢測試劑套件主要設計用於研究環境而非診斷應用，對於研究基因融合及其與各種疾病（尤其是癌症）的關係的科學家和研究人員來說至關重要。隨著對這些工具的需求不斷成長，研究領域預計將在全球基因融合測試市場中保持主導地位。

從技術角度來看，NGS（次世代定序）領域預計將在 2024 年主導全球基因融合檢測市場。 NGS 是一種新興的變革性技術，可提供 DNA 和 RNA 序列的高通量和準確分析，並在基因融合檢測中發揮關鍵作用。在基因融合檢測中，NGS有助於全面檢測基因重排，以便能夠以極高的準確度精確識別不同基因之間的融合事件。隨著NGS的不斷發展，預計它將在全球基因融合檢測市場中保持主導。

根據適應症，預計固態腫瘤領域將在 2024 年引領全球基因融合檢測市場。在腫瘤學中，固態腫瘤的基因融合檢測是分子診斷的重要組成部分，專注於識別由癌細胞中的染色體重排和易位引起的特定基因融合。這些基因融合導致異常融合蛋白的產生，並在固體癌的進展和發展中發揮重要作用。隨著對精準癌症診斷的需求不斷增加，固體癌領域預計將在全球基因融合檢測市場中保持主導地位。

根據最終用戶，預計製藥和生物技術公司將在 2024 年佔據全球基因融合檢測市場的最大佔有率。這些公司在市場中發揮關鍵作用，利用他們的專業知識和資源推動這個快速發展的領域的創新和進步。製藥和生物技術公司深刻認知到基因融合檢測的巨大潛力，主導主要企業癌症診斷和治療策略的革新，確保全球基因融合檢測市場的持續成長和發展。

歐洲市場以德國為主，預計英國的成長率最高。英國正採取合作方式開發基因融合檢測技術。此外，該國以其強大的學術研究機構而聞名，這些機構在推動基因檢測技術和推動全球基因融合檢測市場的創新方面發揮關鍵作用。

基因融合檢測市場是醫療保健產業的一個重要領域，致力於開發、生產和商業化用於檢測和分析基因融合的測試和技術。此測試可識別異常融合事件，即兩種不同的基因融合在一起形成功能改變的融合蛋白，這些事件通常與各種疾病有關，尤其是癌症。本研究探討了推動基因融合檢測進步的幾種核心技術，包括聚合酵素鏈鎖反應(PCR)、次世代次世代定序(NGS)、免疫組織化學 (IHC) 和螢光原位雜合技術(FISH)。全球基因融合檢測市場的擴張受到創新技術的不斷引入以及政府和私營部門不斷增加的投資和資金籌措的推動。

工作流程/創新策略：基因融合檢測市場依適應症分為固體癌和骨髓惡性腫瘤。此外，本研究對基因融合檢測在固體癌中的多種應用進行了徹底的分析，讓讀者全面了解其在識別與這些特定癌症類型相關的基因融合中的作用。

成長/行銷策略：基因融合測試是一種分子診斷技術，用於識別和分析癌細胞中的特定基因變化。當兩個不同的基因（通常位於不同的染色體上）異常融合在一起，形成混合基因，產生具有改變功能的獨特蛋白質時，就會發生這種情況。

競爭策略：該研究對全球基因融合測試市場的主要企業（包括製造商）進行了全面的分析和分析。此外，它還對這些參與企業進行了深入的競爭基準化分析，讓讀者清楚地了解他們之間的比較情況，並全面了解市場格局。

本報告研究了全球基因融合測試市場，並概述了市場趨勢、類別、技術、適應症、最終用戶和地區，以及參與市場的公司概況。

目錄

執行摘要

第1章 產品定義

第2章 市場範圍

第3章調查方法

第4章 市場概述

  • 基因融合檢測簡介
    • 基因融合檢測的各種技術
    • 基因融合檢測的優點與局限性
    • 當前市場規模和未來成長潛力（百萬美元，2023-2035 年）
    • 人工智慧 (AI) 和機器學習 (ML) 在基因融合測試中的作用
    • 兌換狀態
  • 相關利益者調查回复
    • 對基因融合檢測的認知
    • 了解以下公司的 NGS 服務：
    • 基因融合檢測的介紹與障礙

第5章 產業展望

  • 監管狀況
    • 美國法律要求與框架
    • 歐洲法律要求和框架
    • 亞太地區的法律要求與框架

6. 全球基因融合檢測市場：市場動態

  • 影響分析
  • 市場促進因素
  • 市場限制
  • 市場機會

第7章全球基因融合測試市場：競爭考察

  • 概述
  • 關鍵策略和發展
    • 產品核准和發布
    • 夥伴關係和合作
    • 合併與收購
    • 其他進展
  • 市場佔有率分析
    • 按公司
  • 成長佔有率分析

8. 全球基因融合檢測市場（按類別分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 研究
  • 診斷

9. 全球基因融合檢測（依技術分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 次世代定序（NGS）
  • 螢光原位雜合技術（FISH）
  • 聚合酵素鏈鎖反應（PCR）
  • 免疫組織化學（IHC）

10. 全球基因融合檢測市場（依適應症分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 固態腫瘤
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 甲狀腺癌
    • 其他
  • 造血系統惡性腫瘤

11. 全球基因融合檢測市場，依最終用戶分類（百萬美元），2023 年至 2035 年

  • 概述
  • 製藥和生物技術公司
  • 醫院和診斷實驗室
  • 研究與學術中心

12. 全球基因融合檢測市場（按地區分類）（百萬美元），2023 年至 2035 年

  • 概述
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 其他地區

第13章競爭格局與公司概況

  • 競爭格局
  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics
  • Biocartis
  • Biocare Medical, LLC
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics, Inc.
  • NeoGenomics, Inc.
  • OncoDNA
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific Inc.
Product Code: BHP1416SB

Global Gene Fusion Testing Market Industry Overview

The global gene fusion testing market is a critical component of molecular diagnostics and precision medicine, focused on identifying genetic alterations, specifically gene fusions, that contribute to the development of various diseases, particularly cancer. These tests detect gene rearrangements that may lead to abnormal protein functions, driving cancer progression. As the demand for advanced diagnostic technologies grows, the global gene fusion testing market has become essential in precision medicine, enabling the development of personalized treatments tailored to the unique genetic profiles of individual patients. This market plays a vital role in transforming cancer care, allowing for more targeted and effective therapies based on genetic findings.

In the global gene fusion testing market, several technologies such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) are used to detect gene fusions in various cancers. As advancements continue, the global gene fusion testing market is expected to grow exponentially, offering new opportunities for early diagnosis, precise treatment selection, and improved patient outcomes. The rising demand for personalized medicine further propels the global gene fusion testing market, ensuring that patients receive treatments tailored to their genetic makeup, enhancing the effectiveness of therapies and minimizing side effects.

Market Lifecycle Stage

The global gene fusion testing market is experiencing significant growth, fueled by the rising prevalence of cancer associated with gene fusion mutations. The increasing demand for early detection, precise selection of targeted therapies, and personalized medicine is driving this expansion. Additionally, the growing adoption of gene fusion testing in clinical practice is further accelerating the need for these diagnostic tests in cancer care. As the global gene fusion testing market continues to evolve, it plays a crucial role in enabling more accurate and individualized treatment options for cancer patients, improving overall patient outcomes.

Impact

Gene fusion testing is a diagnostic method that employs molecular analysis to detect and examine genetic abnormalities known as gene fusions. These occur when two distinct genes from different chromosomal regions become abnormally joined, creating a hybrid gene. This fusion can result in the production of abnormal proteins or changes in gene expression, potentially contributing to the development of various diseases, including certain cancers. Cancer progression is influenced by multiple genetic alterations, such as mutations, deletions, amplifications, and rearrangements, with gene fusions being a key factor. The involvement of leading industry players, including Amoy Diagnostics Co., Ltd., Biocartis, Biocare Medical, LLC, Danaher Corporation, and F. Hoffmann-La Roche Ltd., is expected to drive further growth in the global gene fusion testing market.

In addition, AI-powered prediction models offer the potential to minimize the need for time-consuming and expensive laboratory assays by identifying patients who may require additional diagnostic testing. These models could also uncover previously undetected gene fusion events, improving the understanding of the genomic landscape of cancers and supporting the development of targeted therapeutic approaches in the global gene fusion testing market.

Market Segmentation:

Segmentation 1: by Category

  • Research
  • Diagnostic

Research to Continue its Dominance in the by Category Segment

In terms of category type, the research segment is anticipated to lead the global gene fusion testing market in FY2024. The increasing adoption of kits, assays, and accessories has greatly contributed to the growth and prominence of this segment. These research-specific assays and kits, primarily designed for use in research settings rather than diagnostic applications, are vital for scientists and researchers studying gene fusions and their involvement in various diseases, especially cancer. As demand for these tools continues to rise, the research segment is set to maintain its dominant position in the global gene fusion testing market.

Segmentation 2: by Technology

  • NGS
  • FISH
  • PCR
  • IHC

NGS to Continue its Dominance in the Technology Segment

Based on technology, the NGS (Next-Generation Sequencing) segment is projected to dominate the global gene fusion testing market in FY2024. NGS is an advanced and transformative technology that plays a pivotal role in gene fusion testing, providing high-throughput and accurate analysis of DNA and RNA sequences. In the context of gene fusion testing, NGS facilitates a comprehensive examination of genetic rearrangements, enabling the precise identification of fusion events between different genes with exceptional accuracy. As NGS continues to evolve, it is set to maintain its leading position in the global gene fusion testing market.

Segmentation 3: by Indication

  • Solid Tumors
  • Hematological Malignancies

Solid Tumors to Continue its Dominance in the Indication Segment

Based on indication, the solid tumors segment is anticipated to lead the global gene fusion testing market in FY2024. In oncology, gene fusion testing for solid tumors is crucial in molecular diagnostics, focusing on identifying specific gene fusions caused by chromosomal rearrangements or translocations within tumor cells. These gene fusions can result in the production of abnormal fusion proteins, which play a significant role in the progression and development of solid tumors. As the demand for precise cancer diagnostics increases, the solid tumors segment is expected to maintain its dominance in the global gene fusion testing market.

Segmentation 4: by End User

  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Centers

Pharmaceutical and Biotechnology Companies to Continue its Dominance in the End User Segment

Based on end user, the pharmaceutical and biotechnology companies segment is expected to hold the largest share of the global gene fusion testing market in FY2024. These companies play a crucial role in the market, utilizing their expertise and resources to drive innovation and promote advancements in this rapidly evolving field. With a keen understanding of the significant potential of gene fusion testing, pharmaceutical and biotechnology companies are leading efforts to revolutionize cancer diagnostics and treatment strategies, ensuring continued growth and development in the global gene fusion testing market.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

U.K. to Continue its Dominance as the Leading Country in Europe Region

Germany is the dominant market in Europe, with the U.K. projected to experience the highest growth rate. The U.K. has adopted a supportive approach towards the development of gene fusion testing technologies. Furthermore, the country is known for its robust academic and research institutions, which play a critical role in advancing genetic testing technologies and driving innovation in the global gene fusion testing market.

Demand - Drivers and Limitations

Market Demand Drivers:

  • Growing Prevalence of Cancer Driven by Gene Fusion Mutations
  • Expanding Use of Gene Fusion Testing in Targeted Therapy Development
  • Global Increase in Research Funding Focused on Cancer Screening and Prevention

Market Restraints:

  • Challenges Due to the Complexity of the Testing Process
  • Issues with Standardization and Barriers in Reimbursement Policies

Market Opportunities:

  • Growing Demand for Gene Fusion Testing in Clinical Research
  • Utilizing Artificial Intelligence to Predict Gene Fusion Status Across Various Cancer Types

The gene fusion testing market is a crucial segment within the healthcare industry, dedicated to the development, production, and commercialization of tests and technologies aimed at detecting and analyzing gene fusions. This testing identifies abnormal fusion events where two distinct genes merge to form fusion proteins with modified functions, often linked to various diseases, particularly cancer. This study explores several core technologies that have driven advancements in gene fusion testing, including polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in-situ hybridization (FISH). The expansion of the global gene fusion testing market is fueled by the ongoing introduction of innovative technologies and increasing investments and funding from both government and private sectors.

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene fusion testing market, segmented by indication, comprises solid tumors and hematological malignancies. Furthermore, the study provides a thorough analysis of the diverse applications of gene fusion testing in solid tumors, offering readers a comprehensive understanding of its role in identifying gene fusions linked to these specific cancer types.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic technique employed to identify and analyze specific genetic alterations in cancer cells. It occurs when two distinct genes, typically located on different chromosomes, fuse abnormally, creating a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the global gene fusion testing market have been extensively analyzed and profiled in this study, including manufacturers. Furthermore, a detailed competitive benchmarking of these players has been performed to give readers a clear insight into how companies measure up against each other, presenting a comprehensive view of the market landscape.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Detailed secondary research to ensure maximum coverage of manufacturers/suppliers operational in a country.
  • Exact revenue information, up to a certain extent, will be extracted for each company from secondary sources and databases. Revenues specific to product/service/technology will then be estimated for each market player based on fact-based proxy indicators as well as primary inputs.
  • The currency conversion rate has been taken from the historical exchange rate of Oanda and/or other relevant websites.
  • Any economic downturn in the future has not been taken into consideration for the market estimation and forecast.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year.
  • The term "product" in this document may refer to "service" or "technology" as and where relevant.
  • The term "manufacturers/suppliers" may refer to "service providers" or "technology providers" as and where relevant.

Primary Research

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding of the numbers of the various markets for market type
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Food and Drug Administration (FDA), European Medical Agency (EMA), National Medical Product Administration (NMPA), Ministry of Health, Labor, and Welfare (MHLW), Pharmaceutical and Medical Devices Association (PMDA), Frontiers, and World Intellectual Property Organization (WIPO)
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their portfolio
  • Gold standard magazines, journals, whitepapers, press releases, and news articles
  • Databases

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent companies in this market are:

  • Amoy Diagnostics Co., Ltd.
  • Biocartis
  • Biocare Medical, LLC
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.

Companies that are not a part of the aforementioned pool have been well represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

1. Product definition

  • 1.1 Inclusion and Exclusion Criteria

2. Market Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3. Research Methodology

4. Market Overview

  • 4.1 Introduction to Gene Fusion Testing
    • 4.1.1 Different Technologies for Gene Fusion Testing
    • 4.1.2 Advantages and Limitations of Gene Fusion Testing
    • 4.1.3 Current Market Size and Future Growth Potential, $Million, 2023-2035
    • 4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing
    • 4.1.5 Reimbursement Landscape
  • 4.2 Stakeholder's Survey Response
    • 4.2.1 Awareness of Gene Fusion Testing
    • 4.2.2 Familiarity with the NGS Offerings of the Following Companies
    • 4.2.3 Adoption and Barriers for Gene Fusion Testing

5. Industry Outlook

  • 5.1 Regulatory Landscape
    • 5.1.1 Legal Requirements and Frameworks in the U.S.
    • 5.1.2 Legal Requirements and Frameworks in Europe
    • 5.1.3 Legal Requirements and Frameworks in Asia-Pacific
      • 5.1.3.1 Legal Requirements and Framework in China
      • 5.1.3.2 Legal Requirements and Framework in Japan

6. Global Gene Fusion Testing Market: Market Dynamics

  • 6.1 Impact Analysis
  • 6.2 Market Drivers
  • 6.3 Market Restraints
  • 6.4 Market Opportunities

7. Global Gene Fusion Testing Market: Competitive Insights

  • 7.1 Overview
  • 7.2 Key Strategies and Developments
    • 7.2.1 Product Approvals and Launches
    • 7.2.2 Partnerships and Collaborations
    • 7.2.3 Mergers and Acquisitions
    • 7.2.4 Other Developments
  • 7.3 Market Share Analysis
    • 7.3.1 By Company
  • 7.4 Growth-Share Analysis

8. Global Gene Fusion Testing Market (by Category), ($Million), 2023-2035

  • 8.1 Overview
  • 8.2 Research
  • 8.3 Diagnostic

9. Global Gene Fusion Testing (by Technology), ($Million), 2023-2035

  • 9.1 Overview
  • 9.2 Next-Generation Sequencing (NGS)
  • 9.3 Fluorescence In-Situ Hybridization (FISH)
  • 9.4 Polymerase Chain Reaction (PCR)
  • 9.5 Immunohistochemistry (IHC)

10. Global Gene Fusion Testing Market (by Indication), ($Million), 2023-2035

  • 10.1 Overview
  • 10.2 Solid Tumors
    • 10.2.1 Lung Cancer
    • 10.2.2 Breast Cancer
    • 10.2.3 Colorectal Cancer
    • 10.2.4 Thyroid Cancer
    • 10.2.5 Others
  • 10.3 Hematological Malignancies

11. Global Gene Fusion Testing Market (by End User), ($Million), 2023-2035

  • 11.1 Overview
  • 11.2 Pharmaceutical and Biotechnology Companies
  • 11.3 Hospitals and Diagnostic Laboratories
  • 11.4 Research and Academic Centers

12. Global Gene Fusion Testing Market (by Region), ($Million), 2023-2035

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 North America Gene Fusion Testing Market, by Indication
    • 12.2.2 North America Gene Fusion Testing Market (by Country)
      • 12.2.2.1 U.S.
        • 12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)
      • 12.2.2.2 Canada
        • 12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)
  • 12.3 Europe
    • 12.3.1 Europe Gene Fusion Testing Market, by Indication
    • 12.3.2 Europe Gene Fusion Testing Market (by Country)
      • 12.3.2.1 Germany
        • 12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)
      • 12.3.2.2 France
        • 12.3.2.2.1 France Gene Fusion Testing Market (by Indication)
      • 12.3.2.3 U.K.
        • 12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)
      • 12.3.2.4 Italy
        • 12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)
      • 12.3.2.5 Spain
        • 12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)
      • 12.3.2.6 Netherlands
        • 12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)
      • 12.3.2.7 Rest-of-the-Europe
        • 12.3.2.7.1 Rest-of-the-Europe Gene Fusion Testing Market (by Indication)
  • 12.4 Asia-Pacific
    • 12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication
    • 12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)
      • 12.4.2.1 China
        • 12.4.2.1.1 China Gene Fusion Testing Market (by Indication)
      • 12.4.2.2 Japan
        • 12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)
      • 12.4.2.3 India
        • 12.4.2.3.1 India Gene Fusion Testing Market (by Indication)
      • 12.4.2.4 Australia
        • 12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)
      • 12.4.2.5 South Korea
        • 12.4.2.5.1 South Korea Fusion Testing Market (by Indication)
      • 12.4.2.6 Rest-of-Asia-Pacific
        • 12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)
  • 12.5 Latin America
    • 12.5.1 Latin America Gene Fusion Testing Market, by Indication
    • 12.5.2 Latin America Gene Fusion Testing Market (by Country)
      • 12.5.2.1 Brazil
        • 12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)
      • 12.5.2.2 Mexico
        • 12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)
      • 12.5.2.3 Rest-of-Latin America
        • 12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)
  • 12.6 Rest-of-the-World
    • 12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)

13. Competitive Landscape and Company Profiles

  • 13.1 Competitive Landscape
    • 13.1.1 New Offerings
    • 13.1.2 Mergers and Acquisitions
    • 13.1.3 Partnerships, Alliances, and Business Expansion
    • 13.1.4 Funding Activities
    • 13.1.5 Regulatory Approvals
  • 13.2 Amoy Diagnostics Co., Ltd.
    • 13.2.1 Overview
    • 13.2.2 Type Portfolio
    • 13.2.3 Target Customers
    • 13.2.4 Key Professionals
    • 13.2.5 Analyst View
  • 13.3 Arima Genomics
    • 13.3.1 Overview
    • 13.3.2 Product Portfolio
    • 13.3.3 Target Customers
    • 13.3.4 Key Professionals
    • 13.3.5 Analyst View
  • 13.4 Biocartis
    • 13.4.1 Overview
    • 13.4.2 Product Portfolio
    • 13.4.3 Target Customers
    • 13.4.4 Key Professionals
    • 13.4.5 Analyst View
  • 13.5 Biocare Medical, LLC
    • 13.5.1 Overview
    • 13.5.2 Product Portfolio
    • 13.5.3 Target Customers
    • 13.5.4 Key Professionals
    • 13.5.5 Analyst View
  • 13.6 Bio-Rad Laboratories, Inc.
    • 13.6.1 Overview
    • 13.6.2 Product Portfolio
    • 13.6.3 Target Customers
    • 13.6.4 Key Professionals
    • 13.6.5 Analyst View
  • 13.7 F. Hoffmann-La Roche Ltd
    • 13.7.1 Overview
    • 13.7.2 Product Portfolio
    • 13.7.3 Target Customers
    • 13.7.4 Key Professionals
    • 13.7.5 Analyst View
  • 13.8 Guardant Health, Inc
    • 13.8.1 Overview
    • 13.8.2 Product Portfolio
    • 13.8.3 Target Customers
    • 13.8.4 Key Professionals
    • 13.8.5 Analyst View
  • 13.9 Illumina, Inc.
    • 13.9.1 Overview
    • 13.9.2 Product Portfolio
    • 13.9.3 Target Customers
    • 13.9.4 Key Professionals
    • 13.9.5 Analyst View
  • 13.10 Invitae Corporation
    • 13.10.1 Overview
    • 13.10.2 Product Portfolio
    • 13.10.3 Target Customers
    • 13.10.4 Key Professionals
    • 13.10.5 Analyst View
  • 13.11 Myriad Genetics, Inc.
    • 13.11.1 Overview
    • 13.11.2 Product Portfolio
    • 13.11.3 Target Customers
    • 13.11.4 Key Professionals
    • 13.11.5 Analyst View
  • 13.12 NeoGenomics, Inc.
    • 13.12.1 Overview
    • 13.12.2 Product Portfolio
    • 13.12.3 Target Customers
    • 13.12.4 Key Professionals
    • 13.12.5 Analyst View
  • 13.13 OncoDNA
    • 13.13.1 Overview
    • 13.13.2 Product Portfolio
    • 13.13.3 Target Customers
    • 13.13.4 Key Professionals
    • 13.13.5 Analyst View
  • 13.14 PerkinElmer, Inc.
    • 13.14.1 Overview
    • 13.14.2 Product Portfolio
    • 13.14.3 Target Customers
    • 13.14.4 Key Professionals
    • 13.14.5 Analyst View
  • 13.15 QIAGEN N.V.
    • 13.15.1 Overview
    • 13.15.2 Product Portfolio
    • 13.15.3 Target Customers
    • 13.15.4 Key Professionals
    • 13.15.5 Analyst View
  • 13.16 Thermo Fisher Scientific Inc.
    • 13.16.1 Overview
    • 13.16.2 Product Portfolio
    • 13.16.3 Target Customers
    • 13.16.4 Key Professionals
    • 13.16.5 Analyst View

List of Figures

  • Figure: Global Gene Fusion Testing Market, Dynamics Impact Analysis
  • Figure: Global Gene Fusion Testing Market Coverage
  • Figure: Global Gene Fusion Testing Market, Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Gene Fusion Testing Market, Patent Analysis, January 2022-March 2025
  • Figure: Global Gene Fusion Testing Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: Global Gene Fusion Testing Market Dynamics, Impact Analysis
  • Table: Global Gene Fusion Testing Market (by Category), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by Technology), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by Indication), $Million, 2023-2035
  • Table: Global Gene Fusion Testing Market (by End User), $Million, 2023-2035